2024
Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategiesSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStay
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapy
2022
Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure
Rodriguez J, Tormey C. Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure. Immunohematology 2022, 38: 96-99. PMID: 36190197, DOI: 10.21307/immunohematology-2022-049.Peer-Reviewed Case Reports and Technical NotesConceptsAmerican Rare Donor ProgramRed blood cell unitsAntigen-positive unitsLife-saving procedurePotential clinical significanceMultiple comorbiditiesKnee amputationExtremity amputationCritical anemiaCase reportAdverse reactionsClinical significanceCell unitsPatient plasmaTransfusion communityGroup OClinical necessityDonor ProgramRBC unitsPatientsAmputationCompatible unitsAnemiaChallenging caseRare eventAssociation of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBlood
2020
Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingFc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
Zerra PE, Arthur CM, Chonat S, Maier CL, Mener A, Shin S, Allen JWL, Baldwin WH, Cox C, Verkerke H, Jajosky RP, Tormey CA, Meeks SL, Stowell SR. Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. Frontiers In Immunology 2020, 11: 905. PMID: 32582142, PMCID: PMC7295897, DOI: 10.3389/fimmu.2020.00905.Peer-Reviewed Original ResearchConceptsAnti-FVIII antibody formationAnti-FVIII antibodiesKnockout recipientsAntibody formationWT recipientsFc gamma receptorsAnti-FVIII antibody developmentGamma receptorsRole of FcγRsFVIII exposureAntibody levelsWT miceTherapeutic optionsAntibody responseC3 knockoutTarget antigenHemophilia AImmune systemFcγRAntibody developmentInfusionRecipientsAntibodiesPotential mechanismsPatientsThe use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis
Zheng Y, Tormey CA. The use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis. Transfusion Medicine 2020, 30: 304-307. PMID: 32342588, DOI: 10.1111/tme.12683.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsThromboembolic eventsFour-factor prothrombin complex concentrateLevel 1 trauma centerAdditional prospective studiesRetrospective observational studyProthrombin complex concentrateOff-label useEmergent surgeryOral anticoagulantsMost patientsClinical outcomesTrauma centerHgb levelsProspective studyLabel indicationsComplex concentrateSevere hemorrhageObservational studyHemorrhage sizePatientsCoagulopathyAdministrationBleedingHemorrhagePassive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series
Sostin N, Ross R, Balbuena‐Merle R, Hendrickson JE, Tormey CA. Passive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. Journal Of Clinical Apheresis 2020, 35: 224-226. PMID: 32110829, DOI: 10.1002/jca.21773.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsRh immune globulin administrationRisk/benefit ratioApheresis platelet transfusionImmune globulin administrationRhIG immunoprophylaxisImmune globulinTransfusion supportAlloantibody formationCase seriesNegative recipientsAlloimmunization riskRhIG administrationReproductive agePassive transferPLT transfusionsTransfusionBlood bankBenefit ratioRhIGApheresis PLTsAdministrationImmunoprophylaxisPatientsSettingCost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting
2019
Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionResponders
2018
Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia
Chandler JB, Siddon AJ, Bahel P, Torres R, Rinder HM, Tormey CA. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia. Journal Of Clinical Pathology 2018, 72: 177. PMID: 30463936, DOI: 10.1136/jclinpath-2018-205438.Peer-Reviewed Original ResearchFalse-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restrictionVery low rate of anti‐D development in male, primarily immunocompetent patients transfused with D‐mismatched platelets
Curtis G, Scott M, Orengo L, Hendrickson JE, Tormey CA. Very low rate of anti‐D development in male, primarily immunocompetent patients transfused with D‐mismatched platelets. Transfusion 2018, 58: 1568-1569. PMID: 29949189, DOI: 10.1111/trf.14614.Peer-Reviewed Original ResearchRisk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, Study‐III N. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database. British Journal Of Haematology 2018, 181: 672-681. PMID: 29675950, PMCID: PMC5991618, DOI: 10.1111/bjh.15182.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnemia, Sickle CellArthritis, RheumatoidBlood DonorsBlood Group AntigensChildChild, PreschoolDatabases, FactualErythrocyte TransfusionFemaleHumansImmunizationInfantIsoantibodiesLupus Erythematosus, SystemicMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsTransfusion ReactionConceptsRed blood cell alloimmunizationRecipient EpidemiologyRecipients databaseSignificant RBC alloantibodiesNegative antibody screenLargest RBCStandardized registryPositive patientsRBC alloantibodiesAntibody screenICD9/10 codesPatient cohortRisk factorsResponder statusCertain diagnosisBlood typeLarger studyAlloimmunizationRhD statusStudy databaseRespondersPatientsDisease associationsPotential correlatesEpidemiology
2017
A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia
Zheng Y, Pollak J, Henderson K, Hendrickson JE, Tormey CA. A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia. Transfusion 2017, 58: 775-780. PMID: 29210083, DOI: 10.1111/trf.14451.Peer-Reviewed Original ResearchConceptsHereditary hemorrhagic telangiectasiaRBC alloimmunization rateAlloimmunization rateHHT patientsRBC transfusionHemorrhagic telangiectasiaRed blood cell transfusionProphylactic antigen matchingBlood cell transfusionTertiary care facilityMultiple arteriovenous malformationsAutosomal dominant disorderCommon alloantibodiesHHT populationCell transfusionSurgical bleedingTransfusion burdenAntigen matchingSpontaneous hemorrhageRetrospective studyMedical recordsArteriovenous malformationsCare facilitiesPatientsDisease pathophysiologyHow do we perform and bill for blood bank physician consultative services?
Jhang JS, Francis RO, Winkler A, Tormey C. How do we perform and bill for blood bank physician consultative services? Transfusion 2017, 57: 2311-2318. PMID: 28833250, DOI: 10.1111/trf.14264.Peer-Reviewed Original ResearchConceptsIndividual patientsTertiary care teaching hospitalCurrent Procedural Terminology codesPhysician servicesTransfusion medicine physiciansProcedural Terminology codesHealth care providersComponent therapyProvider educationTransfusion reactionsBlood productsTeaching hospitalClinical significanceInappropriate testingCare providersMedicine physiciansTerminology codesApheresis proceduresPatientsPhysiciansConsultative servicesLaboratory test resultsHealth careMedical servicesMedical directionTherapeutic Plasma Exchange and Its Impact on Drug Levels
Cheng CW, Hendrickson JE, Tormey CA, Sidhu D. Therapeutic Plasma Exchange and Its Impact on Drug Levels. American Journal Of Clinical Pathology 2017, 148: 190-198. PMID: 28821193, DOI: 10.1093/ajcp/aqx056.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangePlasma exchangeCase reportDrug levelsCase seriesCochrane DatabaseMedication levelsPubMed-MedlineDefinitive guidelinesClinical propertiesAdditional studiesDevelopment of consensusDrug removalPeer-reviewed articlesAdditional investigationCurrent literatureTrialsReportClear needLiterature reviewOwn experiencePatientsLevelsA novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization
Celli R, Schulz W, Hendrickson JE, Tormey CA. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sanguinis 2017, 112: 469-472. PMID: 28337751, DOI: 10.1111/vox.12515.Peer-Reviewed Original ResearchIrradiation of Red Blood Cells and Alloimmunization
Tormey CA, Hendrickson JE. Irradiation of Red Blood Cells and Alloimmunization. Lab Medicine 2017, 48: 172-177. PMID: 28340248, DOI: 10.1093/labmed/lmx018.Peer-Reviewed Original ResearchConceptsAlloimmunization rateRBC alloimmunization rateTime of transfusionRBC unit transfusionPostoperative bleedingRed blood cell damageRed blood cellsRBC transfusionCommon diagnosisImmunosuppressive disordersTransfusion recipientsBlood cell damageAnimal modelsStudy subjectsTransfusionControl groupRBC antigensAntibody screeningRBC unitsPatientsBlood cellsCell damageRBCsOxidative damageDiagnosis